Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabis flos refers to the standardized, dried female inflorescences of the *Cannabis sativa* plant, utilized as a medicinal herbal preparation and a research compound in clinical studies. Its primary psychoactive component is delta-9-tetrahydrocannabinol (THC), which functions as a partial agonist at the cannabinoid type 1 (CB1) and type 2 (CB2) receptors within the endocannabinoid system. In the context of research at Leiden University, cannabis flos has been investigated for its effects on the dopaminergic system and its subsequent impact on creative thinking processes, specifically divergent and convergent thinking. The preparation is typically administered via inhalation using a medical-grade vaporizer to ensure precise and reproducible delivery of cannabinoids. As a botanical product, it contains a complex profile of cannabinoids and terpenes that contribute to its overall pharmacological effect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabis flos.